Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16431135 | 0.86 | BCL3 (0.71) | LMNACD274ALDH1A1HPGDMEN1 | |
| SCHEMBL29849856 | 0.86 | BCL3 (0.71) | LMNACD274ALDH1A1HPGDMEN1 | |
| SCHEMBL28024114 | 0.85 | POLB (0.73) | LMNAALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL16054002 | 0.84 | LMNA (0.77) | LMNACD274ALDH1A1HTR1AMAOA | |
| SCHEMBL26757980 | 0.83 | LMNA (0.78) | LMNAALDH1A1MAOBL3MBTL1MEN1 | |
| SCHEMBL618180 | 0.83 | CYP2C19 (0.66) | LMNAALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL30417071 | 0.82 | ALDH1A1 (0.76) | LMNAALDH1A1KMT2APOLBPKM | |
| SCHEMBL4488493 | 0.82 | CD274 (0.77) | CD274ALDH1A1HTR1AMAOAMAOB | |
| SCHEMBL6569882 | 0.82 | CD274 (0.77) | CD274ALDH1A1HTR1AMAOAMAOB | |
| SCHEMBL28079638 | 0.82 | ALDH1A1 (0.70) | LMNACD274ALDH1A1HTR1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
| US-9630970-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9597329-B2 | Aurora kinase inhibitors and methods of making and using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC (US) | 2017-03-21 | — | — | US | disclosed |
| US-9597329-B2 | Aurora kinase inhibitors and methods of making and using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC (US) | 2017-03-21 | — | — | US | disclosed |
| US-9597329-B2 | Aurora kinase inhibitors and methods of making and using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170000787-A1 | AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170000787-A1 | AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170000787-A1 | AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| US-9340540-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9249124-B2 | Aurora kinase inhibitors and methods of making and using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| WO-2015131080-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20140057913-A1 | AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057913-A1 | AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057913-A1 | AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012135641-A2 | AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-1052248-B1 | Process for the preparation of aqueous solutions of diazonium salts | CLARIANT GMBH (DE) | 2003-03-19 | — | — | EP | disclosed |
| US-6207809-B1 | CATALYTIC HYDROGENATION USING THE CORRESPONDING NITRO COMPOUND | CLARIANT GMBH (DE) | 2001-03-27 | — | — | US | disclosed |
| EP-1052248-A1 | Process for the preparation of aqueous solutions of diazonium salts | Clariant GmbH (DE) | 2000-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057913-A1 | AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | AURKC, AURKA, AURKB | LMNA 1295/4885CD274 4264/4885ALDH1A1 3531/4885 |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | LMNA 2078/4885CD274 785/4885ALDH1A1 4827/4885 |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | LMNA 2078/4885CD274 785/4885ALDH1A1 4827/4885 |
| US-20170000787-A1 | AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | AURKC, AURKA, AURKB | LMNA 1295/4885CD274 4264/4885ALDH1A1 3531/4885 |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | LMNA 2078/4885CD274 785/4885ALDH1A1 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.